Does CBD Help with Weed Withdrawal? What Studies Show
Science
31%
Clinical trials used 400 to 800 mg of pharmaceutical-grade CBD daily for withdrawal, but only 31% of commercial products match their labels, making it nearly impossible to replicate those results at home.
Hurd et al., American Journal of Psychiatry, 2019
Hurd et al., American Journal of Psychiatry, 2019
View as imageThe idea of using CBD for weed withdrawal sounds almost paradoxical. You are quitting a cannabis product, and the proposed remedy comes from the same plant. But CBD and THC are pharmacologically distinct compounds with different mechanisms, different effects, and different risk profiles. The question is not whether CBD is "cannabis" in some broad sense. The question is whether it does anything useful for the specific symptoms that make quitting THC difficult.
The short answer: there is preliminary evidence that CBD may help with certain withdrawal symptoms, particularly anxiety and cravings. But "preliminary" is doing real work in that sentence. The research is early, the product market is chaotic, and the gap between what studies test and what you can actually buy is wider than most people realize. Here is what the science actually shows.
Key Takeaways
- Small clinical trials suggest CBD may reduce cannabis use and ease withdrawal symptoms like anxiety and sleep disruption, but the evidence is still early
- CBD works through different brain pathways than THC — it supports the endocannabinoid system without getting you high or creating dependence
- The FDA has not approved CBD for cannabis withdrawal, and most over-the-counter products have inconsistent dosing with almost no regulatory oversight
- Studies used 400 to 800 mg of CBD daily, which is far more than what typical store-bought products deliver — so replicating those results at home is not realistic
- CBD is not a magic fix for withdrawal — it works best, if at all, as one piece of a broader plan that includes sleep hygiene, exercise, and professional support when needed
- Only about 31% of commercial CBD products actually contain what the label says, and roughly 21% have detectable THC — which is a serious problem if you are trying to quit cannabis
Why CBD for Withdrawal Makes Theoretical Sense
CBD for Withdrawal: What Studies Actually Show
More abstinent days; reduced urinary THC
Reduced cue-induced craving and anxiety
Reduced withdrawal severity and cravings
The OTC product problem:
To understand why researchers are interested in CBD for cannabis withdrawal, you need to understand how THC withdrawal works at the biological level. When you use THC regularly, your brain downregulates its endocannabinoid system, reducing the number and sensitivity of CB1 receptors. When you stop, the system is temporarily underactive. That gap between your reduced endocannabinoid tone and what your brain needs to function normally is what produces withdrawal symptoms: anxiety, insomnia, irritability, loss of appetite, and restlessness.
CBD interacts with this system, but not the way THC does. Rather than binding directly to CB1 receptors (which is what gets you high), CBD appears to inhibit FAAH, the enzyme that breaks down anandamide. Anandamide is your body's own endocannabinoid, sometimes called the "bliss molecule." By slowing its breakdown, CBD may effectively raise your natural endocannabinoid levels during the period when they are most depleted.
CBD also acts on serotonin 5-HT1A receptors, which are directly involved in anxiety regulation. This is the same receptor system targeted by buspirone, a prescription anti-anxiety medication. For a deeper look at how CBD and THC differ at the molecular level, see CBD vs THC, the differences that matter. For broader context on what the research supports and does not support about cannabis-derived compounds, the overview of proven medical benefits of cannabis covers the full evidence landscape.
The theory, in plain terms: CBD may partially compensate for the endocannabinoid deficit that drives withdrawal, without reintroducing the compound (THC) you are trying to quit.
What the Clinical Studies Actually Found
The most cited study on CBD for cannabis withdrawal is a proof-of-concept trial by Freeman and colleagues, published in The Lancet Psychiatry.[1] This was a randomized, placebo-controlled, dose-finding study involving 82 participants with cannabis use disorder. Participants received either placebo or CBD at doses of 200 mg, 400 mg, or 800 mg daily for four weeks.
The results were mixed but notable. The 400 mg and 800 mg groups showed significantly more days of abstinence from cannabis than the placebo group. Participants in these groups also showed reduced urinary THC metabolites, confirming they were actually using less cannabis. The 200 mg dose did not separate from placebo.
Self-reported withdrawal symptoms, including anxiety, irritability, and sleep disturbance, also showed improvement in the higher-dose groups, though the study was not specifically powered to detect differences in individual symptoms.
A 2020 case series by Cleirec and colleagues, published in Cannabis and Cannabinoid Research, followed 20 patients who used CBD for cannabis withdrawal. Participants reported reductions in withdrawal severity and cannabis cravings. However, this was an observational study without a control group, which limits what you can conclude from it.
Hurd and colleagues published research in 2019 in the American Journal of Psychiatry examining CBD for opioid cravings and found that CBD (400 mg and 800 mg) significantly reduced cue-induced craving and anxiety compared to placebo. While this studied a different substance, it provides supporting evidence that CBD has measurable anti-craving effects across substance use contexts.
The overall picture: there is a consistent signal across these studies that CBD at doses of 400 mg or higher may reduce cannabis use, cravings, and some withdrawal symptoms. But these are small studies, and no large-scale confirmatory trial has been published. For a full overview of withdrawal symptoms CBD may target, see the cannabis withdrawal complete guide.
The OTC Product Quality Problem
Here is where the practical picture gets complicated. The studies above used pharmaceutical-grade CBD at precise doses of 400 to 800 mg daily, administered under controlled conditions. What you can buy at a gas station, health food store, or online retailer is a fundamentally different product.
The CBD market in the United States is largely unregulated. The FDA has not approved CBD for cannabis withdrawal or any condition other than certain rare seizure disorders (Epidiolex). This means that most CBD products are sold as supplements or wellness products with minimal oversight.
Multiple independent analyses have found alarming inconsistencies. Research on CBD product labeling accuracy has found that only about 31% of products tested contained the amount of CBD stated on the label.[2] Some had significantly less. Some had significantly more. And about 21% contained detectable levels of THC, which is exactly what you do not want if you are trying to quit.
This matters enormously. If the evidence supporting CBD for withdrawal comes from 400 mg daily of pharmaceutical-grade product, and you are taking 25 mg daily of a product that may contain half the labeled amount, you are not replicating the study. You are running an uncontrolled experiment on yourself with an unknown dose.
Practical Guidance If You Want to Try CBD
If you decide to try CBD during withdrawal, here is how to approach it based on what the evidence suggests.
Dose. The effective range in clinical studies was 400 to 800 mg daily. Most commercial products deliver 10 to 50 mg per serving, which is well below the studied range. Getting to a research-level dose with commercial products would be expensive and would require consuming large quantities. Be realistic about this gap.
Product quality. Look for products that provide a certificate of analysis (COA) from an independent, accredited third-party laboratory. The COA should verify cannabinoid content (confirming the CBD amount matches the label and THC is below 0.3%) and test for contaminants like heavy metals, pesticides, and residual solvents. If a company does not provide a COA, that is a red flag.
Timing. Withdrawal symptoms typically peak in the first week and gradually improve over two to four weeks. If CBD helps, the benefit would be most relevant during this acute phase. For background on what to expect during this period, see how to sleep without weed and supplements for weed withdrawal.
Form. Sublingual oils (held under the tongue for 60 to 90 seconds) have better bioavailability than edibles or capsules. This means more of the CBD reaches your bloodstream. Inhaled CBD has the highest bioavailability but may present problems for someone trying to break a smoking or vaping habit.
The psychological question. For some people, using a cannabis-derived product while quitting cannabis creates a mental loophole that makes full abstinence harder. If you find yourself rationalizing expanded use or treating CBD as a replacement ritual rather than a targeted intervention, that is worth examining honestly.
What CBD Cannot Do
CBD is not a cure for cannabis withdrawal. No study has shown that it eliminates withdrawal symptoms entirely or accelerates the biological timeline of receptor recovery. Your CB1 receptors need approximately 28 days to normalize regardless of what you take.
CBD also does not address the behavioral and psychological dimensions of cannabis dependence. The habits, the coping patterns, the social contexts, the reasons you started using heavily in the first place. These are the domains where therapy, structured support, and intentional habit change do the work that no compound can replicate.
And critically: the FDA has not approved CBD for treating cannabis withdrawal or cannabis use disorder. Any product marketed with those specific claims is making an unauthorized health claim.
The Honest Bottom Line
The evidence for CBD and weed withdrawal is genuinely interesting but genuinely incomplete. Small clinical trials show a consistent signal at doses of 400 mg or higher. The biological mechanism is plausible. But the gap between pharmaceutical-grade research products and what most people can actually buy is enormous, and the regulatory vacuum means you cannot be sure what you are getting.
If you are going through withdrawal, the interventions with the strongest evidence remain exercise, sleep hygiene, time, and professional support when symptoms are severe. CBD may eventually prove to be a useful addition to that toolkit. Right now, it is a promising lead, not a proven treatment.
For more on evidence-based approaches to managing withdrawal, see CBD and anxiety research.
If your withdrawal symptoms are severe or worsening after two weeks, professional support is warranted. The SAMHSA National Helpline at 1-800-662-4357 is free, confidential, and available 24/7.
The Bottom Line
CBD for weed withdrawal has preliminary evidence from small clinical trials showing potential benefits at doses of 400 to 800mg daily. Freeman's Lancet Psychiatry proof-of-concept trial found that 400mg and 800mg CBD groups had significantly more days of cannabis abstinence than placebo, with reduced urinary THC metabolites confirming actual reduced use. CBD works through different pathways than THC: it inhibits FAAH (the enzyme that breaks down anandamide), potentially raising natural endocannabinoid levels during the depletion period, and acts on serotonin 5-HT1A receptors involved in anxiety regulation. The critical practical gap is that research uses pharmaceutical-grade CBD at 400 to 800mg daily, while commercial products typically deliver 10 to 50mg per serving. Independent testing found only 31% of commercial products match their labeled CBD content, and 21% contain detectable THC. The FDA has not approved CBD for cannabis withdrawal. CBD does not prevent withdrawal or accelerate CB1 receptor recovery, and it does not address the behavioral and psychological dimensions of dependence.
Frequently Asked Questions
Sources & References
- 1RTHC-02558·Freeman, Tom P et al. (2020). “First clinical trial finds CBD at 400mg and 800mg reduced cannabis use compared to placebo.” The lancet. Psychiatry.Study breakdown →PubMed →↩
- 2RTHC-03939·Johnson, Erin et al. (2022). “Nearly half of CBD products tested had inaccurate labels.” Journal of cannabis research.Study breakdown →PubMed →↩
Research Behind This Article
Showing the 8 most relevant studies from our research database.
Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis.
Murri, Martino Belvederi · 2026
Cannabis use was associated with higher anti-inflammatory biomarkers (SMD = 0.298, PD = 99%) and pro-inflammatory biomarkers (SMD = 0.166, PD = 100%).
The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis.
Weidberg, Sara · 2026
CBD use was significantly more prevalent in North America than Europe across all time periods.
The Pleiotropic Influence of Cannabidiol and Tetrahydrocannabinol on Inflammatory Biomarkers: A Systematic Review and Meta-Analytical Synthesis.
Candeloro, Bruno Moreira · 2025
Pooled estimates showed trivial and imprecise effects: IL-6 (SMD -0.17, p=0.41), IL-8 (SMD -0.30, p=0.06), IL-10 (SMD -0.10, p=0.79), and TNF-alpha (SMD -0.09, p=0.62).
Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks.
Chou, Roger · 2025
THC:CBD oral spray: small pain decrease (MD -0.54/10); high THC: small decrease (MD -0.78/10); CBD alone: no benefit (moderate SOE); THC products caused large dizziness increase (RR 3.57) and sedation increase (RR 5.04)..
Cannabis Use Disorder Associated With Increased Risk of Postoperative Complications After Hip or Knee Arthroplasties: A Meta-analysis of Observational Studies.
Ding, Cheng · 2024
Across 10 studies with 17,981,628 participants, CUD was associated with significantly higher odds of medical complications (OR 1.33), implant-related complications (OR 1.75), cardiac complications (OR 1.95), stroke (OR 2.06), infections (OR 1.68), periprosthetic fracture (OR 1.42), mechanical loosening (OR 1.54), and dislocation (OR 1.88).
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.
Bilbao, Ainhoa · 2022
CBD showed high-grade evidence for epilepsy (SMD -0.5) and moderate-grade for Parkinsonism (SMD -0.41).
Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Silvinato, Antônio · 2022
CBD compared to placebo reduced seizure frequency by 33%, increased 50% seizure reduction by 20%, increased seizure freedom by 3%, and improved caregiver-assessed clinical impression by 21% in patients with refractory epilepsy..
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning, Boudewijn · 2021
CBD reduced primary seizure frequency versus placebo in LGS (treatment ratio 0.70) and Dravet syndrome (0.71) in the overall population.